Genomic instability resulting from homologous recombination DNA repair deficiency (HRD) is a response biomarker to assess ovarian and breast cancer patient eligibility for PARP inhibitor and platinum-based therapies. HRD measurements have the potential to improve cancer therapy, however standardizing and democratizing HRD measurements remains challenging due to their inherent complexity. This cell line-derived HRD reference material can support the development, validation, and routine use of assays determining HRD status in cancer patients.
Derived from tumor and matched-normal human cell lines
Allows blending to desired % tumor content with included SNP-matched normal cell line gDNA
20 µL of both tumor and matched normal gDNA at 25 ng/µL
HRD status validated by targeted Next Generation Sequencing (NGS)
Manufactured in GMP-compliant, ISO 13485-certified facilities
#Genomic Instability Score (GIS) calculated using Illumina TruSight™ Oncology (TSO) 500 HRD RUO assay which calculates a GIS using an algorithm licensed from Myriad Genetics. Illumina TSO 500 HRD is not available in Japan.